Abstract 625P
Background
Tumor markers have been used for cancer screening and monitoring, yet their potential connection with air pollution remains largely unexplored. We aimed to examine the potential association between various air pollutants – including carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), PM2.5, and PM10 – and the levels of tumor markers (AFP, CEA, CA19-9, CA125, and PSA) within the general population.
Methods
Our study included 10,067 men and 9,598 women in its final analysis. We assessed each individual's annual average exposure to five distinct air pollutants: PM2.5, PM10, NO2, SO2, and CO. Additionally, we measured serum concentrations of AFP, CEA, CA19-9, CA125, and PSA.
Results
After adjusting for potential confounding factors, we discovered noteworthy associations. Both men and women demonstrated a negative correlation between annual average exposure to SO2 and PM10 and AFP concentration (all P < 0.05). In men, after multivariate adjustment, exposure to CO, NO2, SO2, and PM10 showed negative correlations with CEA concentration (all P < 0.05). Furthermore, in men, exposure to CO, NO2, and PM10 exhibited positive associations with PSA concentration after multivariate adjustment (all P < 0.05). Among women, a similar multivariate analysis indicated that SO2 exposure was negatively correlated with CEA concentration (all P < 0.05).
Conclusions
Our study presents the first evidence of a potential link between air pollution exposure and tumor markers within the general population. To establish the validity of these associations, further investigations employing prospective analyses are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract